Published in Br J Clin Pharmacol on February 01, 1983
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med (2000) 2.19
Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J Clin Invest (2003) 1.90
The influence of epithelium on the responsiveness of guinea-pig isolated trachea. Br J Pharmacol (1986) 1.82
Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax (1997) 1.65
Investigational A₃ adenosine receptor targeting agents. Expert Opin Investig Drugs (2011) 1.49
A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest (2005) 1.43
Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. Thorax (1995) 1.37
The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta (2010) 1.23
Adenosine metabolism and murine strain-specific IL-4-induced inflammation, emphysema, and fibrosis. J Clin Invest (2006) 1.22
Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One (2010) 1.16
Adenosine and cardiac arrhythmias. BMJ (1992) 1.15
Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther (2009) 1.14
Adenosine receptors and asthma. Br J Pharmacol (2008) 1.14
Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs. J Physiol (2006) 1.11
Adenosine release from stimulated mast cells. Proc Natl Acad Sci U S A (1984) 1.11
Effects of bronchoconstrictors and bronchodilators on a novel human small airway preparation. Br J Pharmacol (1985) 1.09
The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol (2005) 1.08
A3 adenosine receptor signaling contributes to airway mucin secretion after allergen challenge. Am J Respir Cell Mol Biol (2006) 1.07
Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline. Br J Clin Pharmacol (1985) 1.06
Adenosine signaling during acute and chronic disease states. J Mol Med (Berl) (2013) 1.02
Mechanisms of asthma and implications for its prevention and treatment: a personal journey. Allergy Asthma Immunol Res (2013) 1.02
Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. J Allergy Clin Immunol (2008) 1.01
Adenosine A1 receptors mediate mobilization of calcium in human bronchial smooth muscle cells. Am J Respir Cell Mol Biol (2006) 1.01
Adenosine receptor-mediated contraction and relaxation of guinea-pig isolated tracheal smooth muscle: effects of adenosine antagonists. Br J Pharmacol (1988) 1.00
Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5'-monophosphate in non-atopic asthma. Thorax (1987) 1.00
2-Chloroadenosine induction of vagally-mediated and atropine-resistant bronchomotor responses in anaesthetized guinea-pigs. Br J Pharmacol (1990) 0.97
Influence of epithelium on the responsiveness of guinea-pig isolated trachea to adenosine. Br J Pharmacol (1988) 0.96
Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. Br J Pharmacol (1996) 0.93
Adenosine receptors and asthma. Handb Exp Pharmacol (2009) 0.93
Adenosine receptors and asthma in humans. Br J Pharmacol (2008) 0.93
Airway receptors. Postgrad Med J (1989) 0.92
A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther (2005) 0.90
Adenosine: an importance beyond ATP. Br Med J (Clin Res Ed) (1986) 0.89
Circulatory and respiratory effects of infused adenosine in conscious man. Br J Clin Pharmacol (1987) 0.89
Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax (2002) 0.88
Adenosine-induced secretion in the canine trachea: modification by methylxanthines and adenosine derivatives. Br J Pharmacol (1985) 0.87
Bench-to-bedside review: adenosine receptors--promising targets in acute lung injury? Crit Care (2008) 0.85
Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action. Br J Clin Pharmacol (1990) 0.85
Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. Br J Pharmacol (2001) 0.83
Disparity in FcεRI-induced degranulation of primary human lung and skin mast cells exposed to adenosine. J Clin Immunol (2011) 0.83
Psychological factors in asthma. Allergy Asthma Clin Immunol (2008) 0.82
Mechanism of adenosine-induced airways obstruction in allergic guinea pigs. Br J Pharmacol (2006) 0.82
The pulmonary effects of intravenous adenosine in asthmatic subjects. Respir Res (2006) 0.82
Adenosine-induced bronchoconstriction of isolated lung and trachea from sensitized guinea-pigs. Br J Pharmacol (1992) 0.81
Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol (2006) 0.81
IL-4 amplifies the pro-inflammatory effect of adenosine in human mast cells by changing expression levels of adenosine receptors. PLoS One (2011) 0.81
Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma. Thorax (2002) 0.81
Anti-inflammatory effects of inosine in allergic lung inflammation in mice: evidence for the participation of adenosine A2A and A 3 receptors. Purinergic Signal (2013) 0.80
P1 receptors and cytokine secretion. Purinergic Signal (2007) 0.80
The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am (2014) 0.79
Caffeic acid phenethyl ester attenuates IgE-induced immediate allergic reaction. Inflammopharmacology (2012) 0.78
Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells. J Clin Immunol (2013) 0.78
Mast cell involvement in the adenosine mediated airway hyper-reactivity in a murine model of ovalbumin-induced lung inflammation. Br J Pharmacol (2005) 0.77
Involvement of A1 adenosine receptors in altered vascular responses and inflammation in an allergic mouse model of asthma. Am J Physiol Heart Circ Physiol (2010) 0.76
Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation. J Pharmacol Exp Ther (2012) 0.76
Contractile responses to adenosine, R-PIA and ovalbumen in passively sensitized guinea-pig isolated airways. Br J Pharmacol (2002) 0.75
Adenosine and its role in asthma. Indian J Clin Biochem (2001) 0.75
Adenosine receptors and vascular inflammation. Biochim Biophys Acta (2010) 0.75
Dissecting asthma pathogenesis through study of patterns of cellular traffic indicative of molecular switches operative in inflammation. Prog Stem Cell (2015) 0.75
Signature current of SO2-induced bronchitis in rabbit. J Clin Invest (1997) 0.75
Adenosine in heart and lung disease. Proceedings of the first Cardiothoracic Institute Workshop. 30 March 1988, London. Abstracts. Postgrad Med J (1988) 0.75
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne) (2017) 0.75
Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem (1962) 12.79
Inhibition of sympathetic neurotransmission in canine blood vessels by adenosine and adenine nucleotides. Circ Res (1977) 2.30
Effects of beta-adrenergic receptor blockade on airway conductance and lung volume in normal and asthmatic subjects. Br Med J (1969) 1.98
Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain (1977) 1.83
Role of adenylate cyclase in immunologic release of mediators from rat mast cells: agonist and antagonist effects of purine- and ribose-modified adenosine analogs. Proc Natl Acad Sci U S A (1980) 1.82
Effects of some purine derivatives on the guinea-pig trachea and their interaction with drugs that block adenosine uptake. Br J Pharmacol (1976) 1.77
Regulation of adenylate cyclase by adenosine. Mol Cell Biochem (1979) 1.74
On the mechanism of relaxation of tracheal muscle by theophylline and other cyclic nucleotide phosphodiesterase inhibitors. Acta Pharmacol Toxicol (Copenh) (1979) 1.58
Adenosine receptors and the regulation of adenylate cyclase. Adv Cyclic Nucleotide Res (1981) 1.53
Purine receptors in the trachea: is there a receptor for ATP? Br J Pharmacol (1980) 1.46
Pharmacological studies with adenine, adenosine and some phosphorylated derivatives on guinea-pig tracheal muscle. J Pharm Pharmacol (1976) 1.42
Adenosine inhibition of isolated rabbit ileum and antagonism by theophylline. J Pharmacol Exp Ther (1976) 1.29
Influence of tracheal contraction on relaxant effects in vitro of theophylline and isoprenaline. Br J Pharmacol (1981) 1.27
Adenosine relaxation of isolated vascular smooth muscle. Am J Physiol (1976) 1.26
Contribution of prostaglandins and thromboxanes to the adenosine and ATP-induced contraction of guinea-pig isolated trachea. Br J Pharmacol (1982) 1.18
Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol (1979) 1.18
Regulatory role of adenosine in antigen-induced histamine release from the lung tissue of actively sensitized guinea pigs. Biochem Pharmacol (1980) 1.15
Phosphodiesterase inhibition and theophylline. Eur J Respir Dis Suppl (1980) 1.13
Effects of isoproterenol, theophylline and carbachol on cyclic nucleotide levels and relaxation of bovine tracheal smooth muscle. Biochim Biophys Acta (1977) 1.01
Histamine and metacholine challenge in the testing of bronchial reactivity. Scand J Respir Dis Suppl (1974) 0.99
Intravenous salbutamol and aminophylline in asthma: a search for synergy. Thorax (1981) 0.93
The attenuation of epinephrine-dependent adenylate cyclase by adenosine and the characteristics of the adenosine stimulatory and inhibitory sites. Mol Pharmacol (1979) 0.90
[Does cyclic AMP play a part in the bronchodilator effect of theophylline? (author's transl)]. Bull Eur Physiopathol Respir (1980) 0.86
Dipyridamole - is it a bronchodilator? Eur J Respir Dis (1981) 0.85
[Bronchial muscle tone and plasma concentrations of cyclic adenosine monophosphate (author's transl)]. Prax Pneumol (1976) 0.83
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med (1990) 7.46
A self management plan in the treatment of adult asthma. Thorax (1989) 5.85
Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet (2000) 5.66
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet (1988) 4.85
Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med (1999) 4.72
Asthma, wheezing, and school absence in primary schools. Arch Dis Child (1989) 4.57
Mucosal inflammation in asthma. Am Rev Respir Dis (1990) 4.11
Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet (2004) 3.89
Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis (1989) 3.86
Subepithelial fibrosis in the bronchi of asthmatics. Lancet (1989) 3.70
Prevalence of respiratory symptoms among 7 and 11 year old schoolchildren and association with asthma. Arch Dis Child (1989) 3.25
Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax (2001) 3.23
Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. Eur Respir J (1989) 3.12
The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med (1996) 3.10
Descriptive epidemiology of bronchial reactivity in an adult population: results from a community study. Thorax (1987) 3.06
Use of polymerase chain reaction for diagnosis of picornavirus infection in subjects with and without respiratory symptoms. J Clin Microbiol (1993) 3.01
Salbutamol and isoproterenol. A double-blind trial to compare bronchodilator and cardiovascular activity. N Engl J Med (1969) 2.99
T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol (1996) 2.92
Rhinoviruses infect the lower airways. J Infect Dis (2000) 2.83
Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol (1994) 2.73
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ (1993) 2.70
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet (1990) 2.52
Protection against allergen-induced asthma by salmeterol. Lancet (1990) 2.51
Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med (1995) 2.48
Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis (1990) 2.45
Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J (2000) 2.42
Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ (1997) 2.40
Augmentation of permeability in the bronchial epithelium by the house dust mite allergen Der p1. Am J Respir Cell Mol Biol (1995) 2.30
Personal exposures of children to nitrogen dioxide relative to concentrations in outdoor air. Occup Environ Med (2000) 2.29
Dietary antioxidant vitamin intake and lung function in the general population. Am J Respir Crit Care Med (1995) 2.25
Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ (1992) 2.25
Assessment and management of asthma in an accident and emergency department. Thorax (1985) 2.21
Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. Thorax (1984) 2.20
Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ (1996) 2.19
Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax (2005) 2.19
Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1990) 2.14
Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest (1998) 2.13
Sudden death in asthma: discussion paper. J R Soc Med (1983) 2.13
Longitudinal changes in skin-prick test reactivity over 2 years in a population of schoolchildren with respiratory symptoms. Clin Exp Allergy (1992) 2.06
Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Br Med J (Clin Res Ed) (1987) 2.05
The natural history of respiratory symptoms in a cohort of adolescents. Am J Respir Crit Care Med (1998) 2.05
What symptoms predict the bronchial response to histamine? Evaluation in a community survey of the bronchial symptoms questionnaire (1984) of the International Union Against Tuberculosis and Lung Disease. Int J Epidemiol (1989) 2.05
Fatal asthma attack during an inhalation challenge with ultrasonically nebulized distilled water. J Allergy Clin Immunol (1995) 2.04
Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med (1999) 2.02
A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers (2007) 2.02
Bronchoprotective role for endogenous prostaglandin E2. Lancet (1995) 2.01
Response to inhaled histamine and 24 hour sodium excretion. Br Med J (Clin Res Ed) (1986) 2.01
Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med (1995) 1.96
Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax (2001) 1.95
The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med (1984) 1.95
The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax (2008) 1.93
beta-adrenergic agonist resistance in normal human airways. Lancet (1977) 1.91
Estimation and repeatability of the response to inhaled histamine in a community survey. Thorax (1987) 1.85
The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest (2001) 1.85
Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. A longitudinal study. Am Rev Respir Dis (1989) 1.82
Role of adenylate cyclase in immunologic release of mediators from rat mast cells: agonist and antagonist effects of purine- and ribose-modified adenosine analogs. Proc Natl Acad Sci U S A (1980) 1.82
Natural history of asthma in childhood--a birth cohort study. Arch Dis Child (1991) 1.82
Management of asthma in schools. Arch Dis Child (1987) 1.81
Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med (1996) 1.81
Clinical experience of lymphangioleiomyomatosis in the UK. Thorax (2000) 1.80
Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol (1993) 1.78
Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax (1982) 1.77
What's new about hay fever? Br Med J (Clin Res Ed) (1985) 1.76
Acute exposure to diesel exhaust increases IL-8 and GRO-alpha production in healthy human airways. Am J Respir Crit Care Med (2000) 1.75
Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis (1992) 1.75
Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies. Am Rev Respir Dis (1992) 1.73
Effect of atopy on the natural history of symptoms, peak expiratory flow, and bronchial responsiveness in 7- and 8-year-old children with cough and wheeze. A 12-month longitudinal study [published errarum appears in Am Rev Respir Dis 1992 Aug;146(2):540]. Am Rev Respir Dis (1991) 1.73
Bronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicity. Br Med J (Clin Res Ed) (1984) 1.73
Peak flow based asthma self-management: a randomised controlled study in general practice. British Thoracic Society Research Committee. Thorax (1995) 1.72
Different airway inflammatory responses in asthmatic and healthy humans exposed to diesel. Eur Respir J (2004) 1.71
Inhibition of adenosine 5'-monophosphate- and methacholine-induced bronchoconstriction in asthma by inhaled frusemide. Eur Respir J (1990) 1.70
Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax (2004) 1.69
Randomised placebo controlled trial of beta agonist dose reduction in asthma. Thorax (1999) 1.68
Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med (1996) 1.66
The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis (1989) 1.66
How patients use domiciliary oxygen. Br Med J (1978) 1.66
Associations between respiratory symptoms, bronchial response to methacholine, and atopy in two age groups of schoolchildren. Arch Dis Child (1989) 1.66
Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax (1997) 1.65
Quantitative assessment of bronchial beta-adrenoceptor blockade in man. Br J Clin Pharmacol (1979) 1.65
Respiratory symptoms in older people and use of domestic gas appliances. Thorax (1999) 1.65
Is asthma really due to a polarized T cell response toward a helper T cell type 2 phenotype? Am J Respir Crit Care Med (2001) 1.65
Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med (1997) 1.64
Comparison of three techniques of inhalation on the airway response to terbutaline. Thorax (1983) 1.64
The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur Respir J (2006) 1.62
Comparison of PD20 with two alternative measures of response to histamine challenge in epidemiological studies. Eur Respir J (1993) 1.61
Endothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet (1991) 1.59
Dosage and delivery of nebulised beta agonists in hospital. Thorax (1983) 1.59
Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J (2002) 1.58
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J (1999) 1.58
Attitudes and long-term adjustment of patients surviving cardiac arrest. Br Med J (1971) 1.57